The Conversation (0)
Drug wholesaler Symbion is preparing for a billion-dollar public float after its Swiss owner agreed to sell the business to New Zealand’s EBOS Group (NZE:EBO) for $NZ865 million ($730.9m), the Wall Street Journal reported.
Drug wholesaler Symbion is preparing for a billion-dollar public float after its Swiss owner agreed to sell the business to New Zealand’s EBOS Group (NZE:EBO) for $NZ865 million ($730.9m), the Wall Street Journal reported.
As quoted in the market news:
The deal will create Australasia’s largest wholesaler and distributor of healthcare products and is expected to culminate in the merged group seeking a listing on the Australian Securities Exchange by year’s end.
Click here for the full WSJ news report